The Current Ratio as of December 2025 (TTM) for Celyad Oncology S.A. (CLYYF) is 0.66

According to Celyad Oncology S.A.’s latest financial reports and current stock price. The company's current Current Ratio is 0.66. This represents a change of -74.41% compared to the average of 2.58 of the last 4 quarters.

Celyad Oncology S.A. (CLYYF) Historical Current Ratio (quarterly & annually)

How has CLYYF Current Ratio performed in the past?

The mean historical Current Ratio of Celyad Oncology S.A. over the last ten years is 4.23. The current 0.66 Current Ratio has changed 1.46% with respect to the historical average. Over the past ten years (40 quarters), CLYYF's Current Ratio was at its highest in in the June 2015 quarter at 14.61. The Current Ratio was at its lowest in in the June 2010 quarter at 0.

Celyad Oncology S.A. (CLYYF) Current Ratio by Quarter and Year

Discovering the peaks and valleys of Celyad Oncology S.A. Current Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Celyad Oncology S.A. (CLYYF) Average Current Ratio

How has CLYYF Current Ratio performed in the past?

The current Current Ratio of Celyad Oncology S.A. (CLYYF) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

Celyad Oncology S.A. (CLYYF) Current Ratio vs. Peers

How is CLYYF’s Current Ratio compared to its peers?

Celyad Oncology S.A.’s Current Ratio is less than ERYTECH Pharma S.A. (0), less than Molecular Partners AG (1.06), less than XORTX Therapeutics Inc. (9.35), less than Nutriband Inc. (1.78), less than YS Biopharma Co., Ltd. (4.78), less than Sonnet BioTherapeutics Holdings, Inc. (1.02), greater than ZyVersa Therapeutics, Inc. (0.26), greater than Allarity Therapeutics, Inc. (0.08), less than Kiromic BioPharma, Inc. (2.33), greater than Claritas Pharmaceuticals, Inc. (0.16), greater than Intellipharmaceutics International Inc. (0.14), greater than Metacrine, Inc. (0.04), less than ForU Holdings, Inc. (10.15), greater than ChitogenX Inc. (0.03), greater than Aditxt, Inc. (0.01), greater than Palisade Bio, Inc. (0.02), less than Plus Therapeutics, Inc. (1.96), less than Revelation Biosciences, Inc. (1.29), less than Quoin Pharmaceuticals, Ltd. (6.92), less than Virax Biolabs Group Limited (1.95), less than Blue Water Vaccines, Inc. (7.27), greater than Hillstream BioPharma, Inc. (0.08), less than Kiora Pharmaceuticals, Inc. (1.17), less than null (7.76),

Build a custom stock screener for Celyad Oncology S.A. (CLYYF) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Celyad Oncology S.A. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Celyad Oncology S.A. (CLYYF) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Celyad Oncology S.A. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.